BAY-3547926
- Generic Name
- BAY-3547926
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 148
- Registration Number
- NCT06764316
- Locations
- 🇫🇮
Tampere University Hospital, Tampere, Finland
🇫🇮Turku University Hospital, Turku, Finland
🇨🇦University of Alberta - Cross Cancer Institute (CCI), Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath